CINSARC: Complexity INdex in SARComas

APPLICATIONS

  • Around 30,000 new cases of sarcomas are diagnosed every year in the US and EU
  • Sarcomas are rare cancers for which treatments and prognoses can vary widely
  • The classification and prediction of the metastasis risk is particularly difficult and currently the analysis is based on a histological grade.
  • Such analysis is not very accurate and can often leads to sub-optimal patient management

INVENTORS

Frederic CHIBON
Jean-Michel COINDRE
Actions for onCogenesis understanding and Target Identification in ONcology
(ACTION, U 1218)

CONTACT

Nom : Christophe Zabawinski Titre : Chef de Projet Sciences de la Vie Mail : c.zabawinski@ast-innovations.com

DESCRIPTION

  • A molecular signature (67 genes) was identified by a multidisciplinary team of researchers in Bordeaux and published in Nature Medicine in 2010.
  • This signature, called CINSARC (Complexity INdex in SARComas), allows the classification of patients into 2 subgroups of good or poor prognosis depending on the metastasis risk.
  • Applicable for NGS and CGH-array analysis of frozen and FFPE tumor material
  • Efficacy retrospectively validated in the majority of sarcomas through tumor samples

BENEFITS

  • CINSARC is more predictive than the histological grading
  • CINSARC is the future gold standard in sarcoma medical practice

IP

Patent application: WO 2010/122243 A1

MATURATION

The maturation with Aquitaine Science Transfert led to the validation of the CINSARC signature predictive value

By | 2018-02-08T18:03:56+00:00 février 8th, 2018|